Consider a relatively simple scenario: a patient with type 2 diabetes treated with metformin (has no effect on CYPs) who carries reduced function variants in CYP2C9 (*2 or *3 variants) and who is started on gliclazide (CYP2C9/19 substrate). Here, CYP2C9 is linked to type 2 diabetes mellitus.